Epidemiology of Doublet/Multiplet Mutations in Lung Cancers: Evidence that a Subset Arises by Chronocoordinate Events

Background Evidence strongly suggests that spontaneous doublet mutations in normal mouse tissues generally arise from chronocoordinate events. These chronocoordinate mutations sometimes reflect “mutation showers”, which are multiple chronocoordinate mutations spanning many kilobases. However, little is known about mutagenesis of doublet and multiplet mutations (domuplets) in human cancer. Lung cancer accounts for about 25% of all cancer deaths. Herein, we analyze the epidemiology of domuplets in the EGFR and TP53 genes in lung cancer. The EGFR gene is an oncogene in which doublets are generally driver plus driver mutations, while the TP53 gene is a tumor suppressor gene with a more typical situation in which doublets derive from a driver and passenger mutation. Methodology/Principal Findings EGFR mutations identified by sequencing were collected from 66 published papers and our updated EGFR mutation database (www.egfr.org). TP53 mutations were collected from IARC version 12 (www-p53.iarc.fr). For EGFR and TP53 doublets, no clearly significant differences in race, ethnicity, gender and smoking status were observed. Doublets in the EGFR and TP53 genes in human lung cancer are elevated about eight- and three-fold, respectively, relative to spontaneous doublets in mouse (6% and 2.3% versus 0.7%). Conclusions/Significance Although no one characteristic is definitive, the aggregate properties of doublet and multiplet mutations in lung cancer are consistent with a subset derived from chronocoordinate events in the EGFR gene: i) the eight frameshift doublets (present in 0.5% of all patients with EGFR mutations) are clustered and produce a net in-frame change; ii) about 32% of doublets are very closely spaced (≤30 nt); and iii) multiplets contain two or more closely spaced mutations. TP53 mutations in lung cancer are very closely spaced (≤30 nt) in 33% of doublets, and multiplets generally contain two or more very closely spaced mutations. Work in model systems is necessary to confirm the significance of chronocoordinate events in lung and other cancers.

[1]  J. Drake,et al.  Clusters of mutations from transient hypermutability. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[2]  B. Strauss.  Role in tumorigenesis of silent mutations in the TP53 gene. , 2000, Mutation research.

[3]  S. Sommer,et al.  Spontaneous multiple mutations show both proximal spacing consistent with chronocoordinate events and alterations with p53-deficiency. , 2004, Mutation research.

[4]  A. Jackson,et al.  The mutation rate and cancer. , 1998, Genetics.

[5]  S. Sommer,et al.  Evidence for mutation showers , 2007, Proceedings of the National Academy of Sciences.

[6]  Ian Tomlinson,et al.  Selection, the mutation rate and cancer: Ensuring that the tail does not wag the dog , 1999, Nature medicine.

[7]  J. Minna,et al.  Distinct Epidermal Growth Factor Receptor and KRAS Mutation Patterns in Non–Small Cell Lung Cancer Patients with Different Tobacco Exposure and Clinicopathologic Features , 2006, Clinical Cancer Research.

[8]  S S Sommer,et al.  EGFR somatic doublets in lung cancer are frequent and generally arise from a pair of driver mutations uncommonly seen as singlet mutations: one-third of doublets occur at five pairs of amino acids , 2008, Oncogene.

[9]  J. Lavergne,et al.  Human Gene Mutation , 1994 .

[10]  H. Varmus,et al.  Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase Domain , 2005, PLoS medicine.

[11]  K. Loeb,et al.  Multiple mutations and cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[12]  S. Sommer,et al.  Spontaneous microdeletions and microinsertions in a transgenic mouse mutation detection system: analysis of age, tissue, and sequence specificity , 2001, Environmental and molecular mutagenesis.

[13]  S. Sommer,et al.  p53 As a mutagen test in breast cancer , 2002, Environmental and molecular mutagenesis.

[14]  G. Parmigiani,et al.  The Consensus Coding Sequences of Human Breast and Colorectal Cancers , 2006, Science.

[15]  W A Scaringe,et al.  Human germline mutation in the factor IX gene. , 2001, Mutation research.

[16]  B. Strauss.  Silent and multiple mutations in p53 and the question of the hypermutability of tumors. , 1997, Carcinogenesis.

[17]  S. Sommer,et al.  Tandem‐base mutations occur in mouse liver and adipose tissue preferentially as G:C to T:A transversions and accumulate with age , 1999, Environmental and molecular mutagenesis.

[18]  S. Sommer,et al.  Spontaneous tandem-base mutations (TBM) show dramatic tissue, age, pattern and spectrum specificity. , 2003, Mutation research.

[19]  Kathleen A Hill,et al.  Database of somatic mutations in EGFR with analyses revealing indel hotspots but no smoking‐associated signature , 2007, Human mutation.

[20]  J. Drake.  Too Many Mutants with Multiple Mutations , 2007, Critical reviews in biochemistry and molecular biology.

[21]  S. Sommer,et al.  Evidence that proximal multiple mutations in Big Blue transgenic mice are dependent events. , 2000, Mutation research.

[22]  A. Knudson,et al.  Two genetic hits (more or less) to cancer , 2001, Nature Reviews Cancer.

[23]  M Bobrow,et al.  Searching for the 1 in 2,400,000: A review of dystrophin gene point mutations , 1994, Human mutation.

[24]  W A Scaringe,et al.  Reported in vivo splice‐site mutations in the factor IX gene: Severity of splicing defects and a hypothesis for predicting deleterious splice donor mutations , 1999, Human mutation.

[25]  M. Meyerson,et al.  EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. , 2005, The New England journal of medicine.

[26]  L. Loeb,et al.  A mutator phenotype in cancer. , 2001, Cancer research.

[27]  S. Sommer,et al.  The size distributions of proteins, mRNA, and nuclear RNA , 1980, Journal of Molecular Evolution.

[28]  J. Bielas,et al.  Mutator phenotype in cancer: Timing and perspectives , 2005, Environmental and molecular mutagenesis.

[29]  H. Osada,et al.  EGFR point mutation in non‐small cell lung cancer is occasionally accompanied by a second mutation or amplification , 2006, Cancer science.

[30]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.